Summit-based Celgene Corp., a global biopharmaceutical company, announced Monday it has appointed Jennifer Dudinak to senior vice president, global regulatory affairs.
Dudinak will report to Jay Backstrom, chief medical officer, effective immediately.
Dudinak will be responsible for regulatory strategy and serve on the company’s executive committee.
“Jennifer possesses deep regulatory expertise and has a proven record of leading highly-effective cross-functional teams,” Backstrom said. “Jennifer will lead the regulatory strategy at all stages of our pipeline, which is essential to accelerate and expand our portfolio.”
Dudinak has more than 20 years of experience in regulatory affairs. Prior to Celgene she was at GlaxoSmithKline as vice president and head of regulatory affairs for the pharma therapeutic team.
“Strengthening our Regulatory Affairs team is critical to our future success and is a top corporate objective at this stage of Celgene’s growth,” said Mark J. Alles, chairman and CEO of Celgene. “Jennifer is an outstanding addition to Jay’s global leadership team and the executive committee.”
